All In Biotech

Drug Trial Radar · NCT05638282

A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Subcutaneous Doses of Cendakimab in Chinese Healthy Participants

Last checked: Nov 19, 2026Latest source record: Aug 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Feb 15, 2023

Primary completion

Jun 27, 2023

Study completion Jun 27, 2023

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Dec 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the drug levels, safety, and tolerability of cendakimab in healthy male and female Chinese participants.

Conditions

  • Healthy Participants

Interventions

  • CendakimabDrug

    Specified dose on specified days

  • PlaceboDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Serum Concentration (Cmax)Time frame: Predose and at multiple timepoints (up to 105 days) after dosing
  2. Area Under the Serum Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUC(0-T))Time frame: Predose and at multiple timepoints (up to 105 days) after dosing
  3. Area Under the Serum Concentration-time Curve from Time Zero Extrapolated to Infinite Time (AUC(INF))Time frame: Predose and at multiple timepoints (up to 105 days) after dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 0001

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.